Gilead Extends Arcellx Tender Offer to April 24 at $115/Share Plus CVR
summarizeSummary
Gilead Sciences has extended its tender offer to acquire Arcellx, with the new expiration date set for April 24, 2026, at 5:00 P.M. ET. The offer terms remain $115 per share in cash, along with a $5 Contingent Value Right (CVR) payable on March 31, 2030, subject to a sales milestone. This extension provides a crucial update for Arcellx shareholders, confirming the acquisition process is still active and detailing the updated timeline and specific financial terms. For Arcellx, this is a material development regarding its pending acquisition, while for Gilead, it represents a procedural step in a previously announced strategic transaction. Traders will closely monitor the progress towards the new expiration date for the completion of the acquisition.
At the time of this announcement, ACLX was trading at $114.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $47.86 to $114.94. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.